GYN: Ovarian, Fallopian, Peritoneal Cancer Clinical Trials
Category:Adult
Status:Active
Displaying all 24 Trial
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 3
Protocol Number: 14-050
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovari...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 2 / 3
Protocol Number: 16-715
Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer
Phase: 2
Protocol Number: 15-547
A Phase II Study Of Nivolumab/ Bevacizumab
This research study is evaluating two drugs called Nivolumab and Bevacizumab as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 2
Protocol Number: 16-263
The Women Choosing Surgical Prevention (WISP) Trial
The goal of this clinical research study is to compare the changes in female sexual function between patients having interval salpingectomy with delayed oophorectomy (ISDO) with those having risk-r...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 2
Protocol Number: 16-389
This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: I...
Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 1
Protocol Number: 15-505
This phase I trial studies the side effects and best dose of olaparib and Hsp90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the ...
Diagnosis: Breast: Metastatic, GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase: 1
Protocol Number: 17-715
The HOPE Trial:Helping Our Patients Excel
This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with Fitbit devices. The HOPE app was designed to learn about improving qu...
Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer
Phase:
Protocol Number: 16-477
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a p...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Breast: Metastatic
Phase:
Protocol Number: 17-285
This research study will test whether using wearable fitness trackers with or without a social incentive, delivered through a game-based mobile health intervention, increases physical activity and ...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 17-361
Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
This is a Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 17-240
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with ovarian cancer and their caregivers after a hospitalization.
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 17-475
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer....
Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Vulvar Cancer, Radiation Oncology, GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Cervical Cancer
Phase:
Protocol Number: 17-382
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-human, Phase 1b safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every three weeks. Patients with tumor types likely to express NaPi2...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Thyroid Cancer, GYN: Endometrial/Uterine Cancer, Solid Tumor/Phase I, Lung Cancer
Phase:
Protocol Number: 17-621
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovaria...
Diagnosis: GYN: Endometrial/Uterine Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 17-499
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + ...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 17-511
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 18-077
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), trip...
Diagnosis: Breast: Early Stage Disease, GYN: Ovarian, Fallopian, Peritoneal Cancer, Lung Cancer, Solid Tumor/Phase I, Prostate Cancer
Phase:
Protocol Number: 17-687
This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein t...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 18-067
This study is a phase 2, multi-cohort study, which will assess the safety and efficacy of new treatment combinations in patients with recurrent ovarian cancer.
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 18-303
The primary objectives of the Dose Escalation Phase are to assess the safety and pharmacokinetics (PK) in order to determine a maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of R...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 18-227
Primary Objectives: - Phase1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-r...
Diagnosis: Brain/Neuro Cancer: Recurrent Glioblastoma, Head and Neck Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer, Liver Cancer
Phase:
Protocol Number: 18-332
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian canc...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 18-633
This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back. Adavosertib and ol...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
Phase:
Protocol Number: 19-059
